secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2026-10-06T11:45:18+00:00
Accession:  0001437749-26-032107
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Valion Bio names Thomas Jensen Board Chair; touts $35.6M government funding for Entolimod ARS program
--------------------------------------------------------------------------------

- Thomas H. Jensen named Board Chair of Valion Bio; he is CEO and a director of Nasdaq-listed Allarity Therapeutics, which he has led since December 2023.
- Entolimod is an investigational TLR5 agonist being developed as a potential medical countermeasure for acute radiation syndrome (ARS), holding FDA Fast Track and Orphan Drug designations for ARS.
- Entolimod development has received approximately $35.6 million in non-dilutive funding from several U.S. government agencies.
- Jensen said that to the company's knowledge there is no FDA-approved treatment for gastrointestinal ARS; longer term he sees potential in cancer supportive care.
- Jensen is working with Interim CEO Dean Zikria and President/COO/CFO Lisa Wolf; drug supply is controlled through wholly owned U.S.-based CDMO Velocity Bioworks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000143774926032107/0001437749-26-032107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000143774926032107/vbio20261005_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer